Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders
Author:
- A George AwadAAA George Awad
- 1 February 2010
- journal article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 10 (1) , 1-4
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Elevated rates of substance use disorders in non-psychotic siblings of individuals with schizophreniaSchizophrenia Research, 2008
- Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia — Findings from an in vivo SPECT studySchizophrenia Research, 2006
- Co-Occurring Mental and Substance Use Disorders: The Neurobiological Effects of Chronic StressAmerican Journal of Psychiatry, 2005
- Neuroleptic Dysphoria, Comorbid Drug Abuse in Schizophrenia and the Emerging Science of Subjective Tolerability—Towards a New SynthesisJournal of Dual Diagnosis, 2005
- Subjective Effects of AMPT-induced Dopamine Depletion in Schizophrenia Correlation between Dysphoric Responses and Striatal D2 Binding Ratios on SPECT ImagingNeuropsychopharmacology, 2001
- Subjective Experience and Striatal Dopamine D2 Receptor Occupancy in Patients With Schizophrenia Stabilized by Olanzapine or RisperidoneAmerican Journal of Psychiatry, 2000
- Assessment of the patient??s subjective experience in acute neuroleptic treatment: implications for compliance and outcomeInternational Clinical Psychopharmacology, 1996
- Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measuresPsychological Medicine, 1992
- Dopamine, schizophrenia, mania, and depression: Toward a unified hypothesis of cortico-striatopallido-thalamic functionBehavioral and Brain Sciences, 1987
- Bimodal Distribution of Dopamine Receptor Densities in Brains of SchizophrenicsScience, 1984